This study evaluated the short-term cost-effectiveness of the Patient Empowerment Programme (PEP) for diabetes mellitus (DM) in Hong Kong. Propensity score matching was used to select a matched group of PEP and non-PEP subjects. A societal perspective was adopted to estimate the cost of PEP. Outcome measures were the cumulative incidence of all-cause mortality and diabetic complication over a 5-year follow-up period and the number needed to treat (NNT) to avoid 1 event. The incremental cost-effectiveness ratio (ICER) of cost per event avoided was calculated using the PEP cost per subject multiplied by the NNT. The PEP cost per subject from the societal perspective was US$247. There was a significantly lower cumulative incidence of all-cause mortality (2.9% vs 4.6%, P < .001), any DM complication (9.5% vs 10.8%, P = .001) and CVD events (6.8% vs 7.6%, P = .018), in the PEP group.
| INTRODUCTION
Self-management education programmes were shown to be effective in systematic reviews, but whether such programmes are also costeffective is important to health care decision makers who need to allocate limited resources efficiently. Our recent systematic review all DM subjects in public general outpatient clinics (GOPCs) that provide primary care services. 9 Over 90% of PEP subjects currently participate in RAMP, serving as routine clinical practice. We therefore were interested in evaluating the cost-effectiveness of PEP as an addition to RAMP, using empirical cost and effectiveness data from a cohort with up to 5 years of follow up.
| MATERIALS AND METHODS

| Evaluating the 5-year effectiveness of PEP
We selected subjects with DM who had joined RAMP on or before The set-up cost for NGOs and HA was divided by the number of subjects who attended at least 1 PEP session in that cluster, while the ongoing cost was divided by the number of subjects in that cluster in the corresponding financial year and then averaged across the years. Finally, these per cluster costs were averaged across all clusters.
The NGOs reported on volunteer time spent on PEP. These were annualized and valued at the hourly wages of the specific staff, if noted, or the median hourly wage for the Hong Kong population. 10 The use of NGO's own, or other unpaid, venues for PEP were valued based on the rental cost of paid venues reported in that year. These costs were summed and divided by the corresponding number of subjects, and averaged across clusters and years.
A self-administered questionnaire was distributed to 475 subjects in all clusters to collect the travel cost and time used by subjects and accompanying person(s) attending PEP. Time spent attending PEP sessions was measured as an average of 2.5 hours for diseasespecific sessions and 2 hours for generic sessions, and each participant attended an average of 4 sessions, with 2 disease-specific and 2 generic sessions for each subject; 6% of subjects had a companion.
Travel and attendance time was valued using the median hourly wage for subjects and their companions. 10 Co-payments were made by some subjects but were ignored as a transfer payment under the societal perspective.
| Statistical analysis
Characteristics of the matched PEP and non-PEP groups were compared by independent t-test or chi-squared tests. Five-year cumulative incidence of outcomes was calculated for each type of event and compared between groups by chi-squared tests. All statistical analyses were performed in STATA 13 while the cost and costeffectiveness analyses were done using Excel.
| Cost-effectiveness analysis
Only the extra costs of PEP in addition to routine health care were considered, as both groups attended RAMP. We did not discount the cost since the programme cost was a 1-time cost only, that is, all present cost. The number needed to treat (NNT) to avoid 1 event over a 5-year period was estimated for outcomes, which were significantly different between groups. The incremental cost-effectiveness ratio (ICER) was calculated using PEP cost per subject multiplied by the NNT, giving us cost per complication or death avoided during the study period. One-way sensitivity analysis was conducted to test the uncertainties surrounding PEP cost per subject, using the minimum to maximum values of costs reported by the NGOs. Effectiveness was tested with the 95% confidence interval (CI) for events of PEP groups constructed based on Poisson distribution.
3 | RESULTS
| Characteristics of matched PEP and non-PEP groups
After excluding ineligible subjects, 11 600 subjects in the PEP group remained for matching, which yielded 11 581 matched pairs ( Figure S1 ). There were no significant differences between the matched groups (Table S1 ).
| Five-year effectiveness of PEP
The mean follow-up for PEP and non-PEP groups was 53 and 55 months, respectively. There was a significantly lower cumulative incidence of all-cause mortality (2.9% vs 4.6%, P < .001), any diabetic complication (9.5% vs 10.8%, P = .001) and CVD events (6.8% vs 7.6%, P = .018), in the PEP group than in the non-PEP group (Table S2 ). There was no significant difference in the cumulative incidences of DR, ESRD or neuropathy.
| PEP cost per subject
The total societal PEP cost per subject was US$247 with a range across NGOs of US$191 to US$297 (Table 1) . Among these 57%
were provider costs; 38% were subjects' and families' costs and 5%
were community costs.
| Cost-effectiveness of PEP
The incremental cost of PEP vs non-PEP groups was the programme cost above and NNT to avoid a death from any cause is 58, resulting in an ICER of US$14 465 per death ( Table 2 ). The cost to avoid 
| DISCUSSION
The estimated cost of PEP per subject was approximately US$128 to US$256, depending on whether subject costs were included. Of the NGO-ongoing cost, staff cost and other operating expense costs accounted for the greatest variability, while equipment and venue rentals did not cause much variation. The variation in staff cost could be explained by the different grades of staff used, the different number of staff used or the working hours of staff used.
The additional cost to avoid a death from any cause by PEP was US$14 465 (HK$112 827). A local estimate of the statistical value of life saved in HK was at least HK$10 million. 11 By this measure, the cost to avoid 1 death was far below the value and so PEP could be considered cost-effective. Diabetic complications are usually associated with extra health service costs. For example, 1 study in HK estimated that the health service cost for a subject with CVD was 4 to 11 times higher in the event year and 1 to 2 times higher in the subsequent year than that for a subject without CVD. 12 It would be expected that the PEP cost could be compensated for by the reduction in health service utilization because of prevention of complications. In the current calculation of cost-effectiveness, we did not include health service costs in costing, to avoid double counting of 
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